Literature DB >> 33351155

Sex and age differences in COVID-19 mortality in Europe.

Linda Juel Ahrenfeldt1, Martina Otavova2,3, Kaare Christensen2,4,5,6, Rune Lindahl-Jacobsen2,3.   

Abstract

AIM: To examine the magnitude of sex differences in survival from the coronavirus disease 2019 (COVID-19) in Europe across age groups and regions. We hypothesized that men have a higher mortality than women at any given age but that sex differences will decrease with age as only the healthiest men survive to older ages.
METHODS: We used population data from the Institut National D'Études Démographiques on cumulative deaths due to COVID-19 from February to June 2020 in 10 European regions: Denmark, Norway, Sweden, The Netherlands, England and Wales, France, Germany, Italy, Spain and Portugal. For each region, we calculated cumulative mortality rates stratified by age and sex and corresponding relative risks for men vs. women.
RESULTS: The relative risk of dying from COVID-19 was higher for men than for women in almost all age groups in all regions. The overall relative risk ranged from 1.11 (95% confidence interval, CI 1.01-1.23) in Portugal to 1.54 (95% CI 1.49-1.58) in France. In most regions, sex differences increased until the ages of 60-69 years, but decreased thereafter with the smallest sex difference at age 80+ years.
CONCLUSION: Despite variability in data collection and time coverage among regions, the study showed an overall similar pattern of sex differences in COVID-19 mortality in Europe.

Entities:  

Keywords:  Cumulative mortality rates; European regions; Relative risks; SARS-CoV‑2; Sex difference

Mesh:

Year:  2020        PMID: 33351155      PMCID: PMC7755064          DOI: 10.1007/s00508-020-01793-9

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


Introduction

Despite the fact that women suffer greater morbidity than men, particularly late in life [1], women outlive men in almost all countries of the world [2]. This is the case even under the harshest conditions where mortality is very high, e.g. during severe famines and epidemics [3]. Since December 2019, the emergence of the coronavirus disease 2019 (COVID-19) has been reported in Wuhan, China, with infection outbreaks across China and around the world [4, 5]. Data from early reported cases in China suggested that the mortality rate from COVID-19 is higher for infected men than for infected women [6-8] with fatality rates of 2.8% in men vs. 1.7% in women [8]. A recent study from mainland China found that the case fatality rate (CFR, the risk of dying among persons diagnosed with COVID-19) was lower in female patients (4.0%) than in male patients (7.2%); however, sex differences varied between regions and were age-dependent with significant differences among patients aged 30 years and above [9]. In agreement with this finding, the Global Health 50/50 research initiative, which presents an overview of sex-disaggregated data from countries worldwide, demonstrated that despite similar numbers of COVID-19 cases in men and women there is an increased CFR in men [10]. A review collecting epidemiological data on confirmed COVID-19 cases in Europe and China until 1 April 2020 found that the male to female COVID-19 CFRs reported from France, Italy, Spain, Germany, Switzerland and China were relatively homogeneous and ranged between 1.7 and 1.8 [11]. In addition, pooled data from Italy, Spain, Germany and Switzerland comprising 227,219 confirmed cases and 14,364 deaths suggested that although the male to female CFR was consistently elevated through all age groups, the sex difference was most pronounced at middle age, particularly at ages 50–59 years [11]. Correspondingly, data on COVID-19 cases and deaths obtained from outbreaks in China, Italy and New York City demonstrated a higher mortality for men than for women at all ages, with the scale of difference between sexes being consistent with that found for more common causes of mortality, such as heart disease [12]. Here we examine the magnitude of sex differences in survival from COVID-19 across age groups and regions in Europe. This will enable us to investigate the consistency of sex differences across regions and thus to map the epidemiology of the disease; however, due to the highly variable rate of COVID-19 by age, also the age-specific mortality from COVID-19 is considered. We hypothesized that men have higher mortality than women at any given age, but that sex differences in mortality from COVID-19 will decrease with age as only the healthiest men survive to older ages [1].

Material and methods

Study population

This study was based on 10 European regions (Denmark, Norway, Sweden, The Netherlands, England and Wales, France, Germany, Italy, Spain and Portugal) that reported daily cumulative deaths due to COVID-19 by sex and age available from the Institut National D’Études Démographiques (INED) website [13]. The data collection methods and the time period covered differed for each region with the earliest date of 14 February 2020 and the latest date of 29 June 2020 (see Supplementary Table 1). Sex-specific and age-specific population sizes (numbers) for the 10 European regions can be found in Supplementary Table 2.

Statistical analysis

Sex-specific cumulative mortality rates (CMR) from COVID-19 per 100,000 men and women were calculated for each day for the covered time periods in each region. In addition, CMR and relative risks (RR) with 95% confidence intervals (CI) were calculated in each region in four age groups (<60 years, 60–69 years, 70–79 years and 80+ years) using data from the last day covered by the study. The Wald test was used to investigate differences between the RRs of adjacent age groups.

Results

In all European regions, the CMRs increased with advancing age (Table 1). The highest CMRs were found in England and Wales with 91.0 (95% CI 89.9–92.1) per 100,000 men and 72.4 (95% CI 71.4–73.3) per 100,000 women. High CMRs were also found in two Southern European regions, Italy (66.2, 95% CI 65.3–67.2 per 100,000 men and 45.4, 95% CI 44.7–46.2 per 100,000 women) and Spain (50.3, 95% CI 49.4–51.2 per 100,000 men and 37.2, 95% CI 36.4–38.0 per 100,000 women). The regions with the lowest mortality from COVID-19 were Norway (5.0, 95% CI 4.2–5.9 per 100,000 men and 4.3, 95% CI 3.6–5.2 per 100,000 women), Denmark (11.8, 95% CI 10.6–13.2 per 100,000 men and 8.9, 95% CI 7.9–10.0 per 100,000 women), and Germany (12.1, 95% CI 11.8–12.5 per 100,000 men and 9.5, 95% CI 9.2–9.8 per 100,000 women) (Table 1). The patterns for the CMRs between February and June 2020 revealed an overall similar trend for men and women; however, higher CMRs were found for men than for women, particularly in Western and Southern Europe (Supplementary Fig. 1).
Table 1

Cumulative mortality rates (CMRs) of COVID-19 per 100,000 men and women and relative risks (RRs) for men vs. women with 95% confidence intervals (CIs) over age groups by 10 European regions

CMR95% CICMR95% CIRR95% CI
Denmark
Overall11.84(10.64–13.18)8.92(7.88–10.01)1.33(1.13–1.56)
<60 years0.55(0.96–0.99)0.23(0.08–0.58)2.33(0.82–6.61)
60–69 years11.34(8.10–1.58)6.52(4.19–10.10)1.74(1.03–2.95)
70–79 years45.88(38.29–54.94)16.54(12.36–22.05)2.77(1.99–3.86)a
80+ years157.62(135.28–183.55)112.92(97.50–13.07)1.40(1.13–1.72)a
Norway
Overall4.95(4.17–5.88)4.32(3.58–5.21)1.15(0.89–1.47)
<60 years0.43(0.21–0.84)0.10(0.02–0.40)4.27(0.92–19.76)
60–69 years6.17(3.77–9.96)1.03(0.27–3.29)5.97(1.76–20.28)
70–79 years18.04(12.94–25.03)8.44(5.23–13.45)2.14(1.23–3.71)a
80+ years76.30(59.81–97.16)64.87(52.53–80.03)1.18(0.86–1.61)a
Sweden
Overall52.27(50.33–54.29)46.11(44.27–48.01)1.13(1.07–1.20)
<60 years3.65(3.09–4.31)1.20(0.87–1.62)3.03(2.17–4.24)
60–69 years40.22(35.18–45.97)16.53(13.40–20.37)2.43(1.91–3.10)
70–79 years142.07(131.69–153.25)76.42(69.11–84.49)1.86(1.64–2.10)a
80+ years773.56(737.25–811.64)573.95(548.22–600.86)1.35(1.26–1.44)a
The Netherlands
Overall39.13(37.83–40.48)31.59(30.43–32.80)1.24(1.18–1.30)
<60 years1.98(1.66–2.36)0.97(0.75–1.26)2.04(1.50–2.76)
60–69 years31.98(28.68–35.66)15.78(13.51–18.42)2.03(1.68–2.44)
70–79 years142.95(134.45–151.95)74.26(68.44–80.58)1.92(1.74–2.13)
80+ years601.69(574.82–629.79)393.81(376.57–411.82)1.53(1.43–1.62)a
England and Wales
Overall90.99(89.90–92.09)72.36(71.40–73.32)1.26(1.23–1.28)
<60 years9.00(8.62–9.40)5.06(4.77–5.36)1.78(1.66–1.91)
60–69 years100.84(97.32–104.48)50.04(47.64–52.57)2.01(1.90–2.14)a
70–79 years296.63(289.67–303.75)156.15(151.39–161.07)1.90(1.82–1.97)a
80+ years1234.8(1214.91–1254.77)848.04(834.55–861.75)1.46(1.42–1.48)a
France
Overall34.81(34.18–35.46)22.65(22.16–23.17)1.54(1.49–1.58)
<60 years3.45(3.22–3.69)1.69(1.54–1.86)2.04(1.81–2.29)
60–69 years42.82(40.78–44.97)15.88(14.71–18.65)2.70(2.46–2.95)a
70–79 years114.51(110.45–118.71)43.42(41.14–45.82)2.64(2.47–2.81)
80+ years390.98(381.06–401.15)203.60(19.82–20.91)1.92(1.85–1.99)a
Germany
Overall12.11(11.77–12.45)9.50(9.21–9.80)1.27(1.22–1.33)
<60 years1.01(0.91–1.14)0.40(0.33–0.48)2.55(2.06–3.16)
60–69 years12.63(11.67–13.67)4.21(3.69–4.81)2.99(2.57–3.49)a
70–79 years38.79(36.77–40.92)15.76(14.59–17.02)2.46(2.42–2.70)a
80+ years131.46(126.53–136.57)89.09(85.94–92.35)1.48(1.40–1.55)a
Italy
Overall66.24(65.31–67.17)45.42(44.68–46.18)1.46(1.43–1.49)
<60 years5.37(5.06–5.69)1.85(1.67–2.04)2.91(2.59–3.26)
60–69 years73.80(70.99–76.71)21.12(19.70–22.64)3.49(3.23–3.78)a
70–79 years226.55(220.96–232.28)83.51(80.41–86.73)2.71(2.59–2.83)a
80+ years594.16(582.36–606.20)373.17(365.98–380.49)1.59(1.55–1.63)a
Spain
Overall50.27(49.37–51.20)37.18(36.41–37.96)1.35(1.32–1.39)
<60 years3.76(3.48–4.06)1.74(1.55–1.95)2.17(1.89–2.48)
60–69 years50.41(47.70–53.26)19.72(18.11–21.47)2.56(2.31–2.83)a
70–79 years187.42(181.13–193.93)73.52(69.95–77.28)2.55(2.40–2.70)
80+ years597.80(583.26–612.70)362.22(353.52–371.13)1.65(1.60–1.70)a
Portugal
Overall16.12(15.02–17.30)14.49(13.50–15.55)1.11(1.01–1.23)
<60 years1.30(9.69–1.75)0.66(0.44–0.99)1.96(1.21–3.19)
60–69 years16.29(13.28–19.94)6.65(4.93–8.95)2.45(1.72–3.48)
70–79 years43.76(37.74–50.72)21.87(18.21–26.25)2.00(1.59–2.52)
80+ years192.50(175.44–211.20)140.14(129.22–151.98)1.37(1.22–1.55)a

aSignificant differences in relative risks between age groups (the specific age group and the age group above)

Cumulative mortality rates (CMRs) of COVID-19 per 100,000 men and women and relative risks (RRs) for men vs. women with 95% confidence intervals (CIs) over age groups by 10 European regions aSignificant differences in relative risks between age groups (the specific age group and the age group above) When investigating the RRs for men vs. women, we found higher mortality among men in all age groups except from ages <60 years for Denmark and Norway and ages 80+ years for Norway (Table 1). The overall RRs ranged from 1.11 (95% CI 1.01–1.23) in Portugal to 1.54 (95% CI 1.49, 1.58) in France; however, the overall RR in Norway was non-significant (RR = 1.15, 95% CI 0.89–1.47). In most regions, sex differences increased from ages <60 years to 60–69 years but decreased thereafter (Table 1). Although not all differences in RRs between adjacent age groups were significant, differences in RRs between the oldest age groups were significant in all regions (Table 1). The largest sex differences were found at ages 60–69 years in Norway, England and Wales, Germany and Italy, up to age 69 years in Sweden, up to age 79 years in the Netherlands, France and Portugal, from 60–79 years in Spain and at ages 70–79 years in Denmark. The smallest sex difference was found at ages 80+ years in all regions (Table 1). Supplementary Fig. 2 illustrates the RRs for men vs. women in the four age groups across Europe. We found the largest sex difference in Norway (RR = 4.27, 95% CI 0.92–19.76), Sweden (RR = 3.03, 95% CI 2.17–4.24), and Italy (RR = 2.91, 95% CI 2.59–3.26) for people below age 60 years, in Norway (RR = 5.97, 95% CI 1.76–20.28), Italy (RR = 3.49, 95% CI 3.23–3.78) and Germany (RR = 2.99, 95% CI 2.57–3.49) for people aged 60–69 years, in Denmark (RR = 2.77, 95% CI 1.99–3.86), Italy (RR = 2.71, 95% CI 2.59–2.83) and France (RR = 2.64, 95% CI 2.47–2.81) for people aged 70–79 years and in France (RR = 1.92, 95% CI 1.85–1.99), Spain (RR = 1.65, 95% CI 1.60–1.70) and Italy (RR = 1.59, 95% CI 1.55–1.63) for people aged 80+ years (Supplementary Fig. 2 and Table 1). Overall, the largest sex differences in COVID-19 mortality were found in France, Italy and Spain.

Discussion

By using population estimates from the INED website (February to June 2020) on daily cumulative deaths by age and sex due to COVID-19 in 10 European regions, we found that the risk of death increased with age, and that men had higher mortality from COVID-19 than women in almost all age groups across Europe. In most regions, sex differences increased from ages <60 years to 60–69 years but decreased thereafter with the smallest sex difference at ages 80+ years. Generally, women live longer than men in almost all countries of the world [2]. A recent study investigating the survival in seven populations under extreme conditions from famines, epidemics and slavery found that even when mortality is very high, women survived on average longer than men [3]. Although the biggest contribution to these differentials came from the large mortality differences among infants, the authors found that for all populations, the extreme age, defined as the age to which 5% of the population survived, was higher for women than for men, supporting the hypothesis of an overall ability of females to withstand higher mortality crises better than males [3]. The study supports that the survival advantage of women has fundamental biological underpinnings and also that the female advantage is modulated by a complex interaction of biological, environmental and social factors [3]. The higher mortality from COVID-19 for men than for women was overall similar to that found for other coronaviruses during the last two decades, such as the severe respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome (MERS-CoV) [14-17]. The reasons for the sex differences in COVID-19 are likely multifactorial and include differences in immune response, biological differences between the sexes as well as differences in underlying comorbidities [18-20]. Although recent evidence suggests that European women overall have slightly more comorbidities than European men [21], men are generally reported to have more life-threatening conditions, such as cardiovascular diseases, whereas women tend to have more non-fatal chronic diseases, such as migraine, musculoskeletal and autoimmune diseases as well as physical limitations [22-25]. Thus, the higher risk of death from COVID-19 among men may to some extent be explained by the relatively higher prevalence of underlying comorbidities such as cardiovascular disease, hypertension, diabetes and chronic lung disease [10, 26, 27]. Nevertheless, sex differences in health depend on the selected health dimension and the age group studied, and not all outcomes show differences between sexes or show very little differences [28, 29]. Moreover, men and women occupy different social roles, which makes valid comparisons in health outcomes difficult. When comparing men and women of similar social and economic situations, differences between sexes are generally reduced [28, 30]. Another possible reason for the sex differences in COVID-19 mortality is differences in lifestyle, such as smoking and alcohol consumption between men and women [31]. A systematic review including evidence from five studies found that smokers were 1.4 times more likely than non-smokers to have severe symptoms of COVID-19 and were around 2.4 times more likely to need mechanical ventilation, to be admitted to an intensive care unit or to die compared with non-smokers [32]. Thus, the higher risk-taking behavior in men than in women, including a higher prevalence of male smokers, may also contribute to sex differences in COVID-19 mortality [31, 33, 34]. Although we demonstrated a higher mortality from COVID-19 for men than for women in almost all age groups, we found, as hypothesized, a reduction in the relative risk of mortality for men at later ages, consistent with findings elsewhere [12]. A narrowing of the sex gap with increasing age may be consistent with a survival effect, which leaves the healthiest men in the sample [1]; however, if estrogen protects women from the most serious complications of COVID-19, women may be most protected before the menopause due to the higher serum estrogen levels [35]. Evidence from studies investigating sex differences in COVID-19 mortality stresses the importance of addressing the impact of sex differences on disease epidemics, outbreaks, and pandemics in public health policies and efforts. All regions should report data separately by sex, and research studies should, whenever possible, analyze the interactions between age and sex in COVID-19 morbidity and mortality [11]. The strength of this study was the ability to analyze sex differences in COVID-19 mortality by age groups in 10 European regions showing an overall similar pattern of sex differences, despite the variability in data collection and time coverage among regions. Not all countries have reported data separately by sex, and this study was limited to the European regions providing sex-disaggregated data. Another limitation was that the frequency, recording and reporting of COVID-19 deaths differ from one region to another, but may also differ within regions. The cause of death can be certified by different biological tests, by clinical diagnosis, and by mentioning the infection on the death certificates [13]. Therefore, a cross-national comparison of results should be done with caution. By using population data on daily cumulative deaths due to COVID-19 from 10 European regions, we confirmed a consistently higher mortality from COVID-19 among European men than among European women in almost all age groups. In most regions, sex differences increased from ages <60 years to 60–69 years but decreased thereafter, with the smallest sex difference at ages 80+ years in all regions. This study highlights the importance of addressing the impact of sex on mortality from disease epidemics, but studies using individual-level data are needed to confirm an interaction between age and sex in COVID-19 mortality in order to guide clinical care personnel and to address questions of whether men require additional surveillance, prevention, and earlier intervention than women. Supplementary Fig. 1. Sex-specific cumulative mortality rates (CMR) from COVID-19 per 100,000 men and women with 95% confidence intervals plotted over calendar time between 14 February 2020 and 29 June 2020 for 10 regions in Northern, Western and Southern Europe. Supplementary Fig. 2. Relative risks (RRs) of mortality from COVID-19 for men vs. women in 4 age groups: <60 years, 60–69 years, 70–79 years and 80+ years. Supplementary Table 1—Information on data source and time coverage for each of the 10 European regions included in the study Supplementary Table 2—Sex- and age-specific population sizes (numbers) for the ten European regions included in the study Tables
  32 in total

1.  Sex differences in autoimmune disease.

Authors:  C C Whitacre
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

2.  Hypothesis: Sex-Related Differences in ACE2 Activity May Contribute to Higher Mortality in Men Versus Women With COVID-19.

Authors:  Husam M Salah; Jawahar L Mehta
Journal:  J Cardiovasc Pharmacol Ther       Date:  2020-10-20       Impact factor: 2.457

Review 3.  Men: good health and high mortality. Sex differences in health and aging.

Authors:  Anna Oksuzyan; Knud Juel; James W Vaupel; Kaare Christensen
Journal:  Aging Clin Exp Res       Date:  2008-04       Impact factor: 3.636

4.  Disparities in Age-specific Morbidity and Mortality From SARS-CoV-2 in China and the Republic of Korea.

Authors:  Joseph P Dudley; Nam Taek Lee
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

Review 5.  Sex Differences in Lifespan.

Authors:  Steven N Austad; Kathleen E Fischer
Journal:  Cell Metab       Date:  2016-06-14       Impact factor: 27.287

6.  The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health.

Authors:  Ibrahim G Alghamdi; Issam I Hussain; Shaia S Almalki; Mohamed S Alghamdi; Mansour M Alghamdi; Mohammed A El-Sheemy
Journal:  Int J Gen Med       Date:  2014-08-20

7.  Age-dependent Gender Differences in COVID-19 in Mainland China: Comparative Study.

Authors:  Jie Qian; Lin Zhao; Run-Ze Ye; Xiu-Jun Li; Yuan-Li Liu
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

8.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

9.  COVID-19 and smoking: A systematic review of the evidence.

Authors:  Constantine I Vardavas; Katerina Nikitara
Journal:  Tob Induc Dis       Date:  2020-03-20       Impact factor: 2.600

10.  Sex Differences in Mortality From COVID-19 Pandemic: Are Men Vulnerable and Women Protected?

Authors:  Garima Sharma; Annabelle Santos Volgman; Erin D Michos
Journal:  JACC Case Rep       Date:  2020-05-04
View more
  33 in total

1.  In-hospital mortality in SARS-CoV-2 stratified by sex diffrences: A retrospective cross-sectional cohort study.

Authors:  Mohammed Al-Jarallah; Rajesh Rajan; Raja Dashti; Ahmad Al Saber; Peter A Brady; Hassan Abdelnaby; Moudhi Alroomi; Wael Aboelhassan; Mohammed Abdullah; Noor AlNasrallah; Bader Al-Bader; Haya Malhas; Maryam Ramadhan; Naser Alotaibi; Mohammad Al Saleh; Farah Almutairi; Kobalava D Zhanna
Journal:  Ann Med Surg (Lond)       Date:  2022-06-20

Review 2.  The genetic and evolutionary determinants of COVID-19 susceptibility.

Authors:  Gaspard Kerner; Lluis Quintana-Murci
Journal:  Eur J Hum Genet       Date:  2022-06-28       Impact factor: 5.351

3.  An 18-Month Epidemiologic Survey of 3364 Deceased COVID-19 Cases; a Retrospective Cross-sectional Study.

Authors:  Ayoub Tavakolian; Seyed Hassan Ashrafi Shahri; Mohammad Ali Jafari; Elham Pishbin; Hamid Zamani Moghaddam; Mahdi Foroughian; Hamidreza Reihani
Journal:  Arch Acad Emerg Med       Date:  2022-05-31

4.  [Excess mortality in 2020 in the working-age population of nine Latin American countriesExcesso de mortalidade na população em idade ativa em nove países da América Latina no ano de 2020].

Authors:  Fernando G Benavides; Alejandra Vives; Marta Zimmerman; Michael Silva-Peñaherrera
Journal:  Rev Panam Salud Publica       Date:  2022-06-21

5.  Distinct type I interferon responses between younger women and older men contribute to the variability of COVID-19 outcomes: Hypothesis generating insights from COVID-19 convalescent individuals.

Authors:  Clio P Mavragani; Charalampos Skarlis; Ioannis V Kostopoulos; Eirini Maratou; Paraskevi Moutsatsou; Evangelos Terpos; Ourania E Tsitsilonis; Meletios-Athanasios Dimopoulos; Petros P Sfikakis
Journal:  Cytokine       Date:  2022-07-18       Impact factor: 3.926

6.  A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020-February 2021.

Authors:  Khitam Muhsen; Wasef Na'aminh; Yelena Lapidot; Sophy Goren; Yonatan Amir; Saritte Perlman; Manfred S Green; Gabriel Chodick; Dani Cohen
Journal:  Lancet Reg Health Eur       Date:  2021-06-05

Review 7.  Immunological aspects and gender bias during respiratory viral infections including novel Coronavirus disease-19 (COVID-19): A scoping review.

Authors:  Sabitha Vadakedath; Venkataramana Kandi; Ranjan K Mohapatra; Venkata B K Pinnelli; Richa R Yegurla; Praveen R Shahapur; Vikram Godishala; Senthilkumar Natesan; Kranti S Vora; Khan Sharun; Ruchi Tiwari; Muhammad Bilal; Kuldeep Dhama
Journal:  J Med Virol       Date:  2021-05-19       Impact factor: 20.693

8.  Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis.

Authors:  Megan A Smith; Emily A Burger; Alejandra Castanon; Inge M C M de Kok; Sharon J B Hanley; Matejka Rebolj; Michaela T Hall; Erik E L Jansen; James Killen; Xavier O'Farrell; Jane J Kim; Karen Canfell
Journal:  Prev Med       Date:  2021-05-23       Impact factor: 4.637

9.  Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation.

Authors:  Laura Pérez-Campos Mayoral; María Teresa Hernández-Huerta; Dulce Papy-García; Denis Barritault; Edgar Zenteno; Luis Manuel Sánchez Navarro; Eduardo Pérez-Campos Mayoral; Carlos Alberto Matias Cervantes; Margarito Martínez Cruz; Gabriel Mayoral Andrade; Malaquías López Cervantes; Gabriela Vázquez Martínez; Claudia López Sánchez; Socorro Pina Canseco; Ruth Martínez Cruz; Eduardo Pérez-Campos
Journal:  Mol Cell Biochem       Date:  2021-06-10       Impact factor: 3.396

10.  Spatial clustering and contextual factors associated with hospitalisation and deaths due to COVID-19 in Sweden: a geospatial nationwide ecological study.

Authors:  Osvaldo Fonseca-Rodríguez; Per E Gustafsson; Miguel San Sebastián; Anne-Marie Fors Connolly
Journal:  BMJ Glob Health       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.